Stock Analysis
Editas Medicine, Inc. (EDIT) Stock Analysis
Editas Medicine, Inc. (EDIT) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Editas Medicine, Inc. (EDIT) currently has an AIQ Score of 48/100, indicating a neutral setup. Momentum is the strongest factor at 63/100. Value is the weakest current factor at 34/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
EDIT at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $2.67 |
| AIQ Score | 48/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $471.13M |
| P/E Ratio (TTM) | -4.11 |
| Forward P/E | — |
| EPS (quarter ended 2026-06-30) | -$0.15 |
| Revenue (quarter ended 2026-06-30) | $11.89M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 2.06 |
| Volume | 2.91M |
| 52-week range | $1.66-$3.94 |
| RSI 14 | 50.8 |
| 50-Day SMA | $2.77 |
| 200-Day SMA | $2.68 |
| Analyst Price Target | $5.00 |
| Next Earnings | Nov 9, 2026 |
EDITEditas Medicine, Inc.
Healthcare / Biotechnology
Low Priority
Relative Laggard
Latest quote
- Momentum63
- Value34
- Quality53
- Risk resilience39
- Sentiment—
EDIT Stock Analysis Summary
Editas Medicine, Inc. (EDIT) currently has an AIQ Score of 48/100, indicating a neutral setup. Momentum is the strongest factor at 63/100. Value is the weakest current factor at 34/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, EDIT has AIQ Score of 48/100 with Momentum base of 63/100 and fading Value at 34/100. Wait for component alignment before adding exposure.
Momentum (63/100) leads while Value (34/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -8.87% stock move · EDIT classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is EDIT Bullish or Bearish Right Now?
EDIT currently has a neutral overall setup. Momentum is the strongest factor at 63/100, while Value is weakest at 34/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Momentum is constructive at 63/100.
- - Price is +5.96% above its 50-day SMA.
- - Analyst target implies +87.27% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (35 vs 7).
- - Value is the current constraint at 34/100.
- - Risk Resilience is weak at 39/100.
Current Consensus
EDIT's Technical Analysis Consensus is currently Strong Buy, with 35 buy, 3 neutral, and 7 sell votes. EDIT's 14-day RSI is 50.8, which places the stock in a neutral momentum range. EDIT's beta is 2.06, indicating greater market sensitivity than the broad market.
What Changed in EDIT?
The largest recent change in EDIT is Momentum moving up by 25.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the EDIT Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
EDIT Decision Framework
Public evidence layers, setup checks, and risk context for Editas Medicine, Inc..
Editas Medicine, Inc. (EDIT) Stock Analysis
Editas Medicine, Inc. has an AIQ Score of 48/100 in a Neutral regime. Momentum is strongest at 63/100. Beta is 2, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | EDIT is in a Neutral AIQ regime with score 48/100. |
| Signal Conflict | The primary conflict is that momentum leads at 63/100 while value lags at 34/100. |
| Factor Evidence | Momentum 63/100 · Value 34/100 · Quality 53/100 · Risk 39/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 63/100.
Momentum is 63/100 and RSI (14) is 50.8.
EDIT is in a Neutral regime at 48/100.
Risk factor is 39/100 with beta 2 and annual volatility 81.95%.
Current conflict: momentum leads at 63/100 while value lags at 34/100.
EDIT Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
EDIT Fundamentals
EDIT valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
EDIT Technical Analysis
EDIT technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
EDIT Stock Catalysts
Track EDIT earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
EDIT Dividend Analysis
EDIT dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
EDIT Financial Data
EDIT revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
EDIT Risk Analysis
EDIT volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
EDIT Stock News
EDIT stock news, market tone, recent headlines, and catalyst context.
EDIT vs Gene Editing / Genomics / Biotech Peers
Current peer cohort: EDIT · FATE · FOLD · IBRX · ICLR. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| EDIT Current stock | 48/100 | 34/100 | 63/100 | 39/100 | 0.31 | 81.95% | Current |
| FATE Fate Therapeutics | 34/100 | 34/100 | 48/100 | 34/100 | 0.93 | 88.75% | EDIT vs FATE |
| FOLD Amicus Therapeutics | 41/100 | 35/100 | — | 66/100 | 2.45 | 43.59% | EDIT vs FOLD |
| IBRX ImmunityBio | 56/100 | 34/100 | 46/100 | 28/100 | 1.67 | 106.96% | EDIT vs IBRX |
| ICLR ICON | 61/100 | 67/100 | 93/100 | 41/100 | 0.71 | 68.63% | EDIT vs ICLR |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 29, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts4 recent quarterly periods are available for review.
Checked Oct 31, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching EDIT
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for EDIT
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
EDIT Stock FAQ
What is EDIT stock price today?
Editas Medicine, Inc.'s current stock price is $2.67. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is EDIT bullish or bearish right now?
EDIT's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is EDIT's market cap?
EDIT's market cap is $471.13M based on the latest completed market-close snapshot from Oct 30, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is EDIT's current P/E ratio?
EDIT's current P/E ratio is -4.11 based on the latest completed market-close snapshot from Oct 30, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is EDIT's RSI?
EDIT's 14-day RSI is 50.8 based on the latest completed market-close snapshot from Oct 30, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is EDIT above its 50-day and 200-day moving averages?
EDIT is 5.96% from its 50-day SMA and 9.38% from its 200-day SMA based on the latest completed market-close snapshot from Oct 30, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is EDIT's next earnings date?
EDIT's next earnings date is currently listed as Nov 9, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does EDIT pay a dividend?
EDIT's dividend yield is 0.00% based on the latest completed market-close snapshot from Oct 30, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.